TGFB1 and head and neck cancer: A previous study found that PLT‐derived transforming growth factor‐β (TGF‐β) can activate TGF‐β/Smad and nuclear factor kappa‐B pathways in cancer cells, thereby promoting the epithelial‐mesenchymal transition of tumor cells.23 Antiplatelet drugs, such as aspirin, can improve to some extent the prognosis of patients with head and neck cancers.24 Although ETV and lamivudine have been reported to be capable of reducing PLT count,25, 26 their underlying mechanisms of action remain unclear.